Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?

Advertisement

Related Content

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
Advicor, Simcor Withdrawals Show There's A Lot Riding On CV Outcomes Studies
Where Cholesterol Surrogates Stand After ACC '16
Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?
Keeping Track: FDA Approves Briviact, Refuses To File Firdapse, Rejects Remune
Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?
PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT
LDL Hypothesis Brings Out Skeptics, Supporters At FDA Panel
IMPROVE-IT Study: Negative Panel Review Leaves FDA With Tough Choice

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel